DHA/AA Addition To Infant Formula Not Recommended By LSRO
This article was originally published in The Tan Sheet
Evidence supporting the benefits of arachidonic acid and docosahexaenoic acid in term infant formulas is "insufficient" to warrant a recommendation that the long-chain polyunsaturated fatty acids be added to FDA's nutrient content standards for the products, the American Society for Nutritional Sciences Life Sciences Research Office concludes in a recent report.
You may also be interested in...
COVID-19 Consumer Health Market: Germ-Blocking Nasal Spray, 99.99% Effective Sanitizer, ‘Mask’ To Moisturize Hands
Sensory Cloud’s small study showed FEND nasal solution cut by 99% exhalation of bioaerosol to block COVID-19. Global BioProtect’s hand sanitizer with proprietary antibacterial technology eliminates 45 bacteria, fungi and virus. Trilogy Labs’ solution replenishes moisture in hands irritated by sanitizers.
The addition of n-3 and n-6 long-chain polyunsaturated fatty acids (LCPUFAs) arachidonic acid (AA) and docosahexaenoic acid (DHA) to infant formula did not result in any effect on cognitive and motor development or growth in infants for up to a year-and-a-half, Alan Lucas, MRC Childhood Nutrition Research Centre, London, et al., conclude in a study published in the Dec. 4 issue of The Lancet.
A demonstrated increase in cognitive development in breast-fed infants compared to formula-fed "may be because breast milk provides nutrients required for rapid development of the immature brain," James Anderson, MD, University of Kentucky, et al., conclude in a meta-analysis published in the October issue of the American Journal of Clinical Nutrition.